Understand the immunology partnering landscape using intelligence from 919 real-world collaboration and licensing deals.
Immunology Collaboration and Licensing Deals 2018-2026 provides comprehensive intelligence on 919 partnering deals involving immunology assets, technologies and development programs.
Immunology is a broad and highly active area of life sciences partnering, encompassing multiple disease areas, mechanisms of action, therapeutic technologies and stages of development. Deal structures reflect both the scientific diversity of the field and the different strategies companies use to access, develop and commercialize innovation.
The report brings this activity together in one resource, enabling users to understand who is partnering, which immunology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in immunology partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad immunology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable immunology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking immunology opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable immunology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building immunology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying immunology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Immunology Collaboration and Licensing Deals 2018-2026 provides comprehensive intelligence on 919 partnering deals involving immunology assets, technologies and development programs.
Immunology is a broad and highly active area of life sciences partnering, encompassing multiple disease areas, mechanisms of action, therapeutic technologies and stages of development. Deal structures reflect both the scientific diversity of the field and the different strategies companies use to access, develop and commercialize innovation.
The report brings this activity together in one resource, enabling users to understand who is partnering, which immunology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in immunology partnering.
Understand the immunology partnering landscape
The report analyzes immunology dealmaking from 2018 to 2026, including:
- Trends in immunology partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active immunology dealmakers
- Leading deals by disclosed value
- How immunology partnering activity is evolving
Benchmark immunology deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading immunology dealmakers and prospective partners
The report identifies the most active companies in immunology partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking immunology opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant disease areas
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular mechanisms, technologies or therapeutic approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across immunology indications and targets
Immunology encompasses a wide range of therapeutic indications and biological targets with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad immunology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how immunology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected immunology transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive immunology deal directory
The report includes a comprehensive directory of 919 immunology collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable immunology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking immunology opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable immunology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building immunology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide immunology intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying immunology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in immunology dealmaking
Chapter 3 - Financial deal terms for immunology partnering
Chapter 4 - Leading immunology deals and dealmakers
Chapter 5 - Immunology contract document directory
Chapter 6 - Immunology dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- 4C Biomed
- 4P-Pharma
- 7 Hills Pharma
- 9 Meters Biopharma
- 10X Genomics
- 23andMe
- A*STAR Agency for Science
- Technology and Research
- AB2 Bio
- AB Biosciences
- Abbvie
- AbCellera Biologics
- Abcuro
- Abdul Latif Jameel Health
- ABL Bio
- Ablynx
- Abpro
- AbSci
- Ab Studio
- ABVC BioPharma
- Abveris
- Abzena
- Accro Bioscience
- Accutar Biotechnology
- AcedrA BioPharmaceuticals
- Acelyrin
- Acepodia
- Aclaris Therapeutics
- Acucela
- AcuCort
- Acuitas Therapeutics
- AdAlta
- Adalvo
- Adaptate Biotherapeutics
- Adaptive Biotechnologies
- Adicet Bio
- Adimune
- Aditum Bio
- Aditx Therapeutics
- Aduro BioTech
- Advanz Pharma
- AESOP Technology
- Aevi Genomic Medicine
- Affibody
- AffyXell Therapeutics
- AGC Biologics
- Agenus Bio
- Agility Life Sciences
- AgomAb Therapeutics
- AHN Autoimmunity Institute
- AiCuris
- Aimmune Therapeutics
- AI Proteins
- AirNexis Therapeutics
- Ajinomoto
- Akoya Biosciences
- Akrevia Therapeutics
- Alchemedicine
- Aldeyra Therapeutics
- Alexion Pharmaceuticals
- Alfasigma
- Algen Biotechnologies
- ALK-Abello
- Allegheny General Hospital
- Allen Institute for Immunology
- AllerGenis
- Allogene Therapeutics
- Alloy Therapeutics
- Almirall
- Alpha Cancer Technologies
- Alpine Immune Sciences
- Altamira Pharma
- Alteogen
- Alvotech
- Alyatec
- AlzeCure Pharma
- Amagma Therapeutics
- Ambiopharm
- American Type Culture Collection (ATCC)
- Amgen
- Amphastar Pharmaceuticals
- Amphista Therapeutics
- Ampio Pharmaceuticals
- Amunix
- Amytrx Therapeutics
- AnaMar
- AnaptysBio
- Anergis
- Angany
- Anima Biotech
- Anpac Bio-Medical Science
- Antengene
- Anthropic
- Antibe Therapeutics
- Antisoma Therapeutics
- AOBiome Therapeutics
- Apellis Pharmaceuticals
- Apollo Therapeutics
- Apotex
- Applied BioMath
- AprilBio
- Aptahem
- Aptar Pharma
- Aptorum Group
- Aqemia
- Aqilion
- Aratana Therapeutics
- Arbele
- Arbor Biotechnologies
- Archer Daniels Midland Company
- ArcherDX
- Arcus Biosciences
- Arcutis Biotherapeutics
- Arena Pharmaceuticals
- argenx
- Argonne National Laboratory
- Ariceum Therapeutics
- Aristea Therapeutics
- ARS Pharmaceuticals
- Artelo Biosciences
- Artisan Bio
- Artizan Biosciences
- Asahi Kasei
- Ascendant Health Sciences
- AskAt
- Astellas Pharma
- Astellas Pharma US
- AstraZeneca
- Atara Biotherapeutics
- Atomwise
- ATUM
- Aurigene Discovery Technologies
- Aurinia Pharmaceuticals
- Australian Research Council
- Autolus
- Avacta
- Avactis Biosciences
- Avalere Health
- Avalon GloboCare
- Avalo Therapeutics
- Avectas
- Avicanna
- Aviceda Therapeutics
- Avidity Biosciences
- Avivo Biomedical
- Avrobio
- Axcelead Drug Discovery Partners
- Azenta Life Sciences
- Bausch & Lomb
- Baxalta
- Bayer
- Bayer Animal Health
- BCD Bioscience
- Beacon Discovery
- Becton Dickinson
- Beiersdorf
- Beijing InnoCare Pharma
- Beijing Tianshi Tongda Pharmaceuticals Technology
- Beijing Yuan Jian Health Management
- Belharra Therapeutics
- Benaroya Research Institute
- BenevolentAI
- Bennu Pharmaceuticals
- BeOne Medicines
- Berg
- Berkeley Lights
- Be The Match BioTherapies
- Beth Israel Deaconess Medical Center
- Bicycle Therapeutics
- BigHat Biosciences
- Bill and Melinda Gates Foundation
- Bio-Cancer Treatment International
- Bio-Me
- Bio-Techne
- Bio-Thera Solutions
- BioAegis Therapeutics
- bioAffinity Technologies
- BioAge Labs
- BioBright
- Biocartis
- Biocon
- BioCopy
- BioCryst Pharmaceuticals
- Biocytogen
- BioDuro
- Biogen
- Biohaven Pharmaceuticals
- BioKey
- Biolojic Design
- Biomedical Advanced Research and Development Authority
- BioMed X Innovation Center
- Biomunex Pharmaceuticals
- BioNova Pharmaceuticals
- Bioqube Ventures
- BiosanaPharma
- BioSenic
- Biosion
- BioTuring
- Blacksmith Medicines
- Blau Pharma
- Bloom Science
- BlueRock Therapeutics
- BlueWillow Biologics
- Boehringer Ingelheim
- BostonGene
- Boston Pharmaceuticals
- Bpifrance
- Brain Canada
- BriaCell Therapeutics
- Brickell Biotech
- Bridge Biotherapeutics
- BridGene Biosciences
- Brigham and Women's Hospital
- Bright Peak Therapeutics
- Brii Biosciences
- Bristol-Myers Squibb
- Broad Institute
- Bruno Farmaceutici
- Bryn Pharma
- BullFrog AI
- C4X Discovery
- Cabaletta Bio
- Caelum Biosciences
- California Institute for Regenerative Medicine
- Calliditas Therapeutics
- Calypso Biotech
- Cambridge Enterprise
- Camurus
- Canadian Council
- CANbridge Pharmaceuticals
- Cancer Research Institute
- Candid Therapeutics
- Cantargia
- Carbiotix
- CareFirst BlueCross BlueShield
- Caring Cross
- Carisma Therapeutics
- Carna BioSciences
- Carnegie Mellon University
- Cartesian Therapeutics
- CASI Pharmaceuticals
- Cassie + Friends
- Catalyst Pharmaceuticals
- CB2 Therapeutics
- CDR-Life
- Celgene
- Cellares
- Cellectis
- Cellinfinity Bio
- Cell Mogrify
- Celltrion
- CellType
- Centessa Pharmaceuticals
- Centogene
- Centre Leon Berard
- Century Therapeutics
- Cerecor
- Chai Discovery
- Changchun High & New Technology Industries
- Charite-Universitatsmedizin
- Charite Universitatsmedizin Berlin
- Charles River Laboratories
- Chi-Med
- Children's Hospital Boston
- China Medical System
- Chiome Bioscience
- ChromaDex
- Chromocell
- Chugai Pharmaceutical
- Cincinnati Children’s Hospital Medical Center
- Cipla
- Circuit Clinical
- City of Hope
- ClinConnect
- Clinical Ink
- Clinigen
- CMS Medical
- Coeptis Therapeutics
- Coherus Biosciences
- CoImmune
- Columbia University
- Conduit Pharmaceuticals
- Congruence Therapeutics
- ConsortiaTX
- Corbus Pharmaceuticals
- Corden Pharma
- Cornell University
- Corrona
- COUR Pharmaceutical
- COUR Pharmaceuticals
- Coya Therapeutics
- Crescendo Biologics
- Cristalia
- Cromos Pharma
- Crown Bioscience
- Cryostem
- CSL
- CSL Behring
- CSL Plasma
- CSPC Pharmaceutical Group
- Cue Biopharma
- Cugene
- Cullinan Oncology
- Cullinan Therapeutics
- Curadev Pharma
- Cyclacel Pharmaceuticals
- Cynata Therapeutics
- Cyntar Ventures
- Cyrus Biotechnology
- CytoAgents
- Cytobank
- Cytocom
- CytoLynx Therapeutics
- CytoReason
- CytoSite Bio
- Cytovance Biologics
- CYTOVIA Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Dalhousie University
- Danuo Science Group
- DAS Therapeutics
- DAVI II Farmaceutica
- Dayra Therapeutics
- Decode Health
- Deerfield Management
- Defense Advanced Research Projects Agency
- DEKA Research and Development
- Delta 4
- Denali Therapeutics
- Department of Defense
- Dermira
- Devonian Health Group
- DiaCarta
- Dianomi Therapeutics
- Dianthus Therapeutics
- DKSH
- DNAnexus
- Dong-A ST
- DoveTree Medicines
- Dr. Reddy's Laboratories
- Dragonfly Therapeutics
- Dren Bio
- Dualogics
- Duke University
- DyDo Pharma
- DynamiCure Biotechnology
- Earendil Labs
- Edesa Biotech
- EdiGene
- Editas Medicine
- Egle Therapeutics
- Eilean Therapeutics
- Eisai
- ElevateBio
- Eli Lilly
- Elix
- Elpis Biomed
- Emergex Vaccines
- Enable Biosciences
- Enesi Pharma
- Enlaza Therapeutics
- Enodia Therapeutics
- Enosi Therapeutics
- Entera Bio
- Enterome Bioscience
- Entos Pharmaceuticals
- Enzychem Lifesciences
- EpiAxis Therapeutics
- EpimAb Biotherapeutics
- Epivax
- EQRx
- Equillium
- Erasmus University Medical Center
- ERS Genomics
- Erytech Pharma
- Escient Pharmaceuticals
- Eterna Therapeutics
- Eton Pharmaceuticals
- Eurofins Discovery
- Eurofins Scientific
- European Union
- Eutilex
- Evax
- Evelo Biosciences
- Everest Medicines
- Evidation Health
- Evinova
- Evommune
- EVOQ Therapeutics
- Evotec
- Exagen Diagnostics
- Excelra
- Expert Systems Inc
- Exscientia
- F-Star Therapeutics
- Factor Bioscience
- FairJourney Biologics
- Federal Ministry of Health (Germany)
- Feinstein Institute for Medical Research
- Feldan Therapeutics
- Fibrogen
- Five Prime Therapeutics
- Flagship Pioneering
- Florida State University
- Fluo Labs
- Folia Biotech
- Food Allergy Research & Education
- Food and Drug Administration (FDA)
- Foresee Pharmaceuticals
- Forge Biologics
- Formation Bio
- Formosa Pharmaceuticals
- Fortress Biotech
- Fosun Pharmaceutical
- Fosun Wanbang
- Foundation Medicine
- Foundery Innovations
- Fred Hutchinson Cancer Research Center
- French National Institute for Agricultural Research
- Fresenius Kabi Pharmaceuticals
- Frontier Biotech
- FSD Pharma
- Fujifilm
- FUJIFILM Cellular Dynamics
- Fujifilm Diosynth Biotechnologies
- Fuji Pharma
- Fujirebio Diagnostics
- Fulgent Pharma
- Fundacion Progreso y Salud
- Galapagos
- Galmed Pharmaceuticals
- GC Biopharma
- GC LabCell
- Gedeon Richter
- GE Healthcare
- GEMoaB
- GEn1E Lifesciences
- GenEdit
- Genentech
- GeneQuantum Healthcare
- Generation Bio
- Genesis Therapeutics
- Genmab
- Genovis
- Genrix Bio
- Gensci
- GenScript Biotech
- GentiBio
- Georgetown University
- George Washington University
- Georgiamune
- GeoVax
- Gilead Sciences
- Ginkgo BioWorks
- Glenmark Pharmaceuticals
- Glycovax Pharma
- Gossamer Bio
- Granite Bio
- Graphite Bio
- Graph Therapeutics
- Graviton Bioscience
- Great Ormond Street Hospital (GOSH)
- GSK
- GT Biopharma
- Haisco Pharmaceutical
- HalioDx
- Halozyme Therapeutics
- Hamilton Company
- HanAll Biopharma
- HanchorBio
- Hangzhou Highlightll Pharmaceutical
- Hangzhou Zhongmei Huadong Pharmaceutical
- Hanmi Pharmaceutical
- Hannover Medical School
- Hansa Biopharma
- Harbour Biomed
- Harvard University
- Hebei Senlang Biotechnology
- Hebrew University of Jerusalem
- Helix
- Henlius Biotech
- HIBio
- HiFiBio
- Hikma Pharmaceuticals
- Hinge Bio
- HitGen
- Hologic
- Hookipa Pharma
- Horizon Therapeutics
- Hospital for Special Surgery
- Hoth Therapeutics
- HotSpot Therapeutics
- Huadong Medicine
- Huahui Health
- Hualan Genetic
- Humanigen
- Hutchmed
- Hybridize Therapeutics
- I-mab
- Iambic Therapeutics
- IASO Biotherapeutics
- Icahn School of Medicine at Mount Sinai
- IcanoMAB
- Ichnos Sciences
- Idorsia
- IFM Therapeutics
- Ifowonco Informatics
- IGM Biosciences
- Ildong Pharmaceutical
- Illumina
- ImaginAb
- Imbrium Therapeutics
- ImCheck Therapeutics
- Imcyse
- IMIDomics
- Immatics Biotechnologies
- Immetas Therapeutics
- ImmPACT Bio
- Immugenyx
- Immunai
- ImmuneID
- Immune Pharmaceuticals
- ImmuNext
- Immunic
- Immunitas Therapeutics
- ImmunoAdoptive Cell Therapy
- ImmunoChina Pharmaceuticals
- ImmunoFlex
- ImmunoGenesis
- Immunomic Therapeutics
- Immunscape
- Immutep
- Immuthera
- Imperial College London
- IMU Biosciences
- In4Derm
- INBRAIN Neuroelectronics
- IncellDx
- Incyte
- InDex Pharmaceuticals
- InduPro Therapeutics
- Infinity Pharmaceuticals
- InflamaCORE
- INGENIA Therapeutics
- Inimmune
- Inmagene Biopharmaceuticals
- InnDura Therapeutics
- INNERVIA Bioelectronics
- Innovate UK
- Innovent Biologics
- Inotrem
- Insilico Medicine
- Inspirotec
- Institut Curie
- Institute for Basic Science
- Institute for Bioscience and Biotechnology Research
- Institute of Child Health
- Institute of Human Virology
- Institut Pasteur
- Intarcia Therapeutics
- Intas Pharmaceuticals
- Integral Molecular
- Integrated Biosciences
- Integrated BioTherapeutics
- Intellia Therapeutics
- Intellikine
- Intract Pharma
- Intrommune Therapeutics
- InveniAI
- Invitae
- Iolyx Therapeutics
- iOncologi
- IONTAS
- IQVIA
- iReceptor Plus
- Ironwood Pharmaceuticals
- ISD Immunotech
- IsoPlexis
- Israeli National Authority for Technological Innovation
- Jacobio Pharmaceuticals
- JAMP Pharma Group
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- Janssen Research & Development
- Janssen Therapeutics
- Japan Tobacco
- Jasper Therapeutics
- Jeffrey Modell Foundation
- Jemincare
- Jiangsu Chia Tai Fenghai Pharmaceutical
- Jiangsu Chia Tai Tianqing Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Jiangsu Hengrui Pharmaceuticals
- Jiangsu QYuns Therapeutics
- Jnana Therapeutics
- Johns Hopkins University
- Johnson & Johnson
- Jubilant Therapeutics
- Junshi Biosciences
- Jupiter Neurosciences
- JW Therapeutics
- Kadmon Pharmaceuticals
- Kaigene
- Kaken Pharmaceutical
- Kalbe Genexine Biologics
- Kaleido Biosciences
- Kali Therapeutics
- Kamada
- Karolinska Institute
- Kashiv BioSciences
- KBI BioPharma
- KBP BioSciences
- KeifeRx
- Kelonia Therapeutics
- Kezar Life Sciences
- Kineta
- Kings College London
- Kiniksa Pharmaceuticals
- Kissei Pharmaceutical
- Kite Pharma
- Klaria
- Knight Therapeutics
- Kobe University
- Komodo Health
- KVK-Tech
- KYE Pharmaceuticals
- Kymera Therapeutics
- Kyorin Pharmaceutical
- Kyowa Hakko Kirin
- kyron.bio
- Kyverna Therapeutics
- LabGenius
- Laboratoires Thea
- LABORATORIOS SAVAL
- La Jolla Institute for Allergy & Immunology
- Landmark Bio
- Lantheus Holding
- Laurel Venture Capital
- Lead Pharma
- Lee Moffitt Cancer Center
- LegoChem Biosciences
- Leiden University
- Leidos
- LEO Pharma
- Lepu Biopharma
- Les Laboratoires Servier
- Leveragen
- LG Life Sciences
- Libbs Farmaceutica
- LifeMax Laboratories
- Ligand Pharmaceuticals
- Lipum
- LNC
- LogicBio Therapeutics
- Lonza
- Lorna Linda University
- LTL Pharma
- Luminary Therapeutics
- Luminex
- Lumiphore
- Lundbeck
- Lupin
- Lupus Canada
- Lupus Foundation of America (LFA)
- Lupus Research Alliance
- Lupus Therapeutics
- Lurie Children's Hospital of Chicago
- Luye Pharma Group
- Lynk Pharmaceuticals
- MaaT Pharma
- MAB Discovery
- Mabtech
- mAbXience
- Magenta Therapeutics
- Magnetic Insight
- Makana Therapeutics
- Mallinckrodt Pharmaceuticals
- Marengo Therapeutics
- Marinomed Biotechnologie
- Maruho
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Mass General Brigham
- Matchpoint Therapeutics
- Matica Biotechnology
- Mavatar
- Max Biopharma
- Maxcyte
- Maxion Therapeutics
- Mayo Clinic
- MC2 Therapeutics
- MD Anderson Cancer Center
- MD Biosciences
- Medac
- Mediar Therapeutics
- Medical University of Vienna
- Medical University South Carolina
- MediGene
- Medison Pharma
- Medsenic
- Medvisis
- Meiji Seika
- Memo Therapeutics
- Merck and Co
- Merck KGaA
- Merus
- Mestag Therapeutics
- Metaba
- Metabolon
- Metrion Biosciences
- Microba Life Sciences
- Microbio Shanghai
- Microdrop
- Microsoft
- MIGAL Galilee Research Institute
- MiLaboratories
- Miltenyi Biotec
- Mimetas
- MiNK Therapeutics
- MIODx
- Mirador Therapeutics
- Miralogx
- Mira Pharmaceuticals
- Mitra Biotech
- Mitsubishi Tanabe Pharma
- Moderna
- ModeX Therapeutics
- Molecure
- Monte Rosa Therapeutics
- MoonLake Immunotherapeutics
- MorphoSys
- Mor Research Applications
- Mount Sinai Health System
- Mount Sinai Medical Center
- MS Pharma
- Mundipharma
- Mustang Bio
- Mylan Pharmaceuticals
- Nanjing Hanxin Pharmaceutical Technology
- Nanjing Leads Biolabs
- NanoView Biosciences
- NASA
- National Cancer Institute
- National Heart
- Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
- National Organization for Rare Disorders
- National Research Council Canada
- National Resilience
- National Science Foundation
- National University of Singapore
- Nektar Therapeutics
- Nemysis
- NeoImmuneTech
- Neomorph
- Neovii Pharmaceuticals
- NeoX Biotech
- Neptune Technologies & Bioressources
- Nestle Health Science
- NeuCen BioMed
- Neukio Biotherapeutics
- NeuroCycle Therapeutics
- Newsoara Biopharma
- New Wave Ventures
- Neximmune
- NextCure
- Nichi-Iko Pharmaceutical Co
- NIMML Institute
- NImmune Biopharma
- Nippon Shinyaku
- Nipro Corporation
- NJCTTQ
- Nkarta Therapeutics
- NLC Pharma
- Noga Therapeutics
- Nona Biosciences
- Norgine
- Normunity
- North Carolina State University
- Northwestern University
- Novartis
- Novelty Nobility
- Novo Nordisk
- NTC
- Nuance Pharma
- Numab
- Nurix Therapeutics
- Nuvectis Pharma
- Nxera Pharma
- NYU Langone Medical Center
- Oak Hill Bio
- Ocean Biomedical
- Octagon Research Solutions
- Odyssey Therapeutics
- Oklahoma Medical Research Foundation
- Omega Therapeutics
- Omeros
- Onco-Innovations
- Oncocross
- OncoImmune
- Onegevity
- Oneness Biotech
- oNKo-innate
- Ono Pharmaceutical
- Optimeos Life Sciences
- Oragenics
- Orange Grove Bio
- Orebro University
- Orionis Biosciences
- Oruka Therapeutics
- OSE Immunotherapeutics
- Oslo University Hospital
- Ossium Health
- Otsuka
- Ottimo Pharma
- Ouro Medicines
- Outpace Bio
- Ovation
- Owkin
- Oxford Biomedica Solutions
- Palisade Bio
- Palleon Pharmaceuticals
- Pandion Therapeutics
- Pantherna Therapeutics
- Parse Biosciences
- Parvus Therapeutics
- PathAI
- Pathios Therapeutics
- PatientsLikeMe
- Penn State College of Medicine
- Peptilogics
- Perelman School of Medicine
- Pfizer
- Phanes Therapeutics
- PharmAla Biotech
- Pharming Group
- Phebra
- Philogen
- Phio Pharmaceuticals
- PhoreMost
- Photys Therapeutics
- Pictor
- Pieris Pharmaceuticals
- Pioneering Medicines
- Pionyr Immunotherapeutics
- Plan France Relance
- Plasticell
- Plexision
- Pluristem Therapeutics
- Pneuma Respiratory
- Polpharma Biologics
- Polymed Biopharmaceuticals
- PPD
- Precision BioSciences
- Precision for Medicine
- PredictImmune
- Pregene Biopharma
- Prenosis
- PreventionGenetics
- Primevera Therapeutics
- Priovant Therapeutics
- PRISM BioLab
- ProBioGen
- ProciseDx
- Progentec Diagnostics
- Prokarium
- Prometheus Biosciences
- Prometheus Laboratories
- Proteona
- ProThera
- ProtoKinetix
- Provention Bio
- Provider Network of America
- Purdue Pharma
- Pure Biologics
- PureTech Health
- Pyramid Biosciences
- Q32 Bio
- QuantumCell
- Qu Biologics
- Queensland Institute of Medical Research (QIMR)
- Queensland University of Technology
- Quell Therapeutics
- Quest Diagnostics
- Quibim
- Quinta-Analytica
- Quoin Pharmaceuticals
- Quotient
- R-Pharm
- Rani Therapeutics
- Ra Pharmaceuticals
- RAPT Therapeutics
- Rasayana Therapeutics
- Ratio Therapeutics
- ReAlta Life Sciences
- Recipharm
- Recludix Pharma
- Recordati
- Regeneron Pharmaceuticals
- Regranion
- Relation Therapeutics
- RemeGen
- Remix Therapeutics
- Repertoire Genesis
- Repertoire Immune Medicines
- Repurpose.AI
- Research Foundation to Cure AIDS
- ReveraGen BioPharma
- Revive Therapeutics
- RevolKa
- Revolo Biotherapeutics
- Rheos Medicines
- Ribon Therapeutics
- Richard King Mellon Foundation
- Rigel Pharmaceuticals
- RIKEN Research Institute
- Roche
- Roivant Sciences
- Roswell Biotechnologies
- Royalty Pharma
- RTW Investments
- Rubedo Life Sciences
- Rubicon Research
- Ryvu Therapeutics
- SAB Biotherapeutics
- Sail Biomedicines
- Sai Life Sciences
- Salix Pharmaceuticals
- SAMIL Pharmaceuticals
- Samsung Bioepis
- Sandoz
- Sanford Burnham Institute
- Sanofi
- Santhera Pharmaceuticals
- Sartorius Stedim Biotech
- SATT Lutech
- Scailyte
- Schreiner Group
- Schrodinger
- SciCann Therapeutics
- ScienceMachine
- Scienta Lab
- Scleroderma Research Foundation
- Scripps Research Institute
- Seagen
- Seattle Children's Hospital
- Seattle Childrens Research Institute
- Seattle Genetics
- Secarna Pharmaceuticals
- SecondWave Systems
- Sedec Therapeutics
- Sekris Biomedical
- Selecta Biosciences
- Selecxine
- Selexis
- Sementis
- Sen-Jam Pharmaceutical
- Sengenics
- Senhwa Biosciences
- Senti Biosciences
- Sentivera
- SenzaGen
- Seqirus
- SeraNovo
- Seres Therapeutics
- Shandong Fontacea Pharmaceutical
- Shanghai Model Organisms Center
- Shattuck Labs
- Shire Laboratories
- Sigyn Therapeutics
- Silence Therapeutics
- Simcere Pharmaceutical
- Simcere Zaiming
- Similis Bio
- Sino Biopharm
- Sinorda Biomedicine
- Siolta Therapeutics
- Sirona Dx
- Sitryx
- Sitryx Therapeutics
- Sixty Degrees Pharmaceuticals
- SK Biopharmaceuticals
- Skyhawk Therapeutics
- Solarea Bio
- Solstice Oncology
- SomaLogic
- Sonnet BioTherapeutics
- Sonoma BioTherapeutics
- Sonora Quest Laboratories
- Sosei
- Sosei Heptares
- Sparrow Pharmaceuticals
- SparX Biopharmaceutical
- Spero Therapeutics
- Spring Bank Pharmaceuticals
- SQI Diagnostics
- SQZ Biotech
- St. Jude Children's Research Hospital
- STADA Arzneimittel
- Stallargenes
- Stallergenes Greer
- Stanford University
- Stanford University School of Medicine
- Stony Brook University
- Strand Life Sciences
- Sutro Biopharma
- Suzhou Porton Advanced Solutions
- Suzhou Siran Biotechnology
- Swedish Orphan Biovitrum
- Swixx Biopharma
- Sygnature Discovery
- Symbiotix Biotherapies
- Synaffix
- Syndax Pharmaceuticals
- Synedgen
- Syneron Bio
- Synthekine
- Synthorx
- Sysmex
- T-Cell Protect Hellas
- Tabuk Pharmaceuticals
- TaiMed
- Taisho Pharmaceutical
- Takeda Pharmaceutical
- Takeda Ventures
- Tango Therapeutics
- Tavotek Biotherapeutics
- Tavros Therapeutics
- Tectora Therapeutics
- Teijin
- Tempest Therapeutics
- Tempus
- Tentarix Biotherapeutics
- Terray Therapeutics
- Terumo Blood and Cell Technologies
- Tetra Bio-Pharma
- Tetragenetics
- Teva Pharmaceutical Industries
- TG Therapeutics
- Tharimmune
- Theradiag
- Therapix Bio
- Theravance Biopharma
- Theriva Biologics
- Thorne Research
- Tikomed
- Tissue Dynamics
- Tivic Health Systems
- Tizona Therapeutics
- TJ Biopharma
- Tmunity Therapeutics
- TNAX Biopharma
- Todos Medical
- Tolerance Bio
- TONIX Pharmaceuticals
- Tow Foundation
- Traaser
- Transgene
- Transimmune
- TransThera
- Travere Therapeutics
- Trethera
- TRexBio
- TrialSpark
- Trillium Therapeutics
- Trinity Biotech
- Triumvira Immunologics
- Truveta
- Tsinghua University
- Tufts Medical Center
- Turn Biotechnologies
- Tuteur
- Twist Bioscience
- uBriGene Biosciences
- UCB
- Universite Laval
- University Health Network
- University of Amsterdam
- University of Barcelona
- University of Birmingham
- University of British Columbia
- University of Buffalo
- University of Calgary
- University of California
- San Diego
- University of California Berkeley
- University of California Los Angeles
- University of California San Francisco
- University of Cambridge
- University of Chicago
- University of Cincinnati
- University of Connecticut
- University of Edinburgh
- University of Erlangen
- University of Georgia
- University of Houston
- University of Kiel
- University of Lethbridge
- University of Maryland Baltimore
- University of Massachusetts Medical School
- University of Michigan
- University of Minnesota
- University of Montreal
- University of New South Wales
- University of North Texas Health Science Center
- University of Oxford
- University of Pennsylvania
- University of Pittsburgh
- University of Sheffield
- University of Texas Southwestern Medical Center
- University of Toronto
- University of Utah
- University of Verona
- University of Virginia
- University of Western Ontario
- University of West Indies
- University of Wisconsin-Madison
- University of Zurich
- Unnatural Products
- Uppsalagruppen Medical
- ValenzaBio
- Validus Pharmaceuticals
- Valneva
- Valo Health
- Vanderbilt University
- Vanqua Bio
- Variant Pharmaceuticals
- Ventus Therapeutics
- Veraxa Biotech
- Verily
- Veritas
- Vertex Pharmaceuticals
- Vetter
- Viatris
- Viela Bio
- Vignette Bio
- Vinnova
- Viome
- Vipergen
- Viridian Therapeutics
- Visterra
- Vitalli Bio
- Vittoria Biotherapeutics
- Vividion Therapeutics
- Vivoryon Therapeutics
- Vivtex
- VolitionRX
- Voluntis
- Vor Bio
- Voronoi
- Voro Therapeutics
- vTv Therapeutics
- Vycellix
- VyGen-Bio
- VYNE Therapeutics
- Washington University in St Louis
- Waters Corporation
- Wellcome Trust
- Wellcome Trust Sanger Institute
- WellGen
- Werfen Group
- Western University
- WestGene Biopharma
- Whitehead Institute
- Willow Biosciences
- Windgap Medical
- Windward Bio
- Wisconsin Alumni Research Foundation
- WuXi Advanced Therapies
- WuXi Biologics
- WuXi XDC
- Wyss Institute
- X-chem
- X4 Pharmaceuticals
- Xencor
- Xilio Therapeutics
- XtalPi
- Xyphos Biosciences
- Y-Biologics
- Yale University
- Yangtze River Pharmaceutical Group
- Yarrow Bioscience
- Yeda Research and Development Company
- ZAI Laboratory
- Zealand Pharma
- Zenas BioPharma
- Zenyaku Kogyo
- Zura Bio
- Zylo Therapeutics
- Zymeworks
- ZyVersa Therapeutics
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
